Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.37 (
neutrophil elastase
)
4,078
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The human lysosomal cysteine-type carboxypeptidase
cathepsin X
is mainly present in monocytes and macrophages and may be released into the circulation due to constitutive and/or regulated secretion by (activated) immune cells. To define its potential diagnostic value as an inflammatory marker, we have developed a highly sensitive and specific sandwich-type immunoassay (ELISA) for
cathepsin X
permitting both intra- and extracellular detection and quantification. The dynamic range of the
cathepsin X
ELISA was determined to be 100 (detection limit) to 8000 pg/ml. Reproducibility of both within and between runs yielded coefficients of variation (CVs) of 2.7-3.5% and 6.3-7.3%, respectively. Cross-reactivity with other members (cathepsin B, L) of the thiol-dependent cathepsin family was not observed. The ELISA was used to quantify
cathepsin X
in leukocytes as well as in plasma of healthy volunteers and patients with multiple trauma. During the first 72 h after trauma, plasma levels of
cathepsin X
increased significantly, particularly in patients who died during the posttraumatic period. In comparison to the well-known inflammation marker
neutrophil elastase
,
cathepsin X
levels predicted survival with a higher significance in the later posttraumatic phase. In conclusion, this report provides the first evidence of
cathepsin X
immunoreactivity not only in cell lysates but also in plasma samples. We suggest that the newly developed highly reproducible ELISA will be of great value for further evaluation of this protease as a diagnostic and/or prognostic marker in inflammatory diseases.
...
PMID:An enzyme-linked immunosorbent assay for human cathepsin X, a potential new inflammatory marker. 1637 71